These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
173 related articles for article (PubMed ID: 3027853)
1. Ketoconazole vs. itraconazole for antifungal prophylaxis in patients with severe granulocytopenia: preliminary results of two nonrandomized studies. Tricot G; Joosten E; Boogaerts MA; Vande Pitte J; Cauwenbergh G Rev Infect Dis; 1987; 9 Suppl 1():S94-9. PubMed ID: 3027853 [TBL] [Abstract][Full Text] [Related]
2. Itraconazole versus ketoconazole for the prophylaxis of fungal infection in neutropenic children: results of two consecutive nonrandomized studies. Ninane J; Sluysmans T; Vermylen C; De Beule K; Woestenborghs R; Cauwenbergh G; Cornu G Pediatr Hematol Oncol; 1989; 6(4):349-53. PubMed ID: 2561916 [TBL] [Abstract][Full Text] [Related]
3. Antifungal prophylaxis with itraconazole in prolonged neutropenia: correlation with plasma levels. Boogaerts MA; Verhoef GE; Zachee P; Demuynck H; Verbist L; De Beule K Mycoses; 1989; 32 Suppl 1():103-8. PubMed ID: 2561181 [TBL] [Abstract][Full Text] [Related]
4. [Therapy of systemic mycoses in neutropenic patients using itraconazole. A comparative, randomized study with amphotericin B]. van't Wout JW; Novakova I; Verhagen CA; Fibbe WE; de Pauw BE; van der Meer JW Med Klin (Munich); 1991 Dec; 86 Suppl 1():11-3. PubMed ID: 1663200 [TBL] [Abstract][Full Text] [Related]
5. Possible failure of itraconazole in preventing fungal infection in a neutropenic leukaemia patient. van der Hoven ; Hendriks WD; Sizoo W Eur J Clin Microbiol Infect Dis; 1992 Feb; 11(2):202-4. PubMed ID: 1327788 [No Abstract] [Full Text] [Related]
6. Preliminary results of treatment with itraconazole in patients with systemic fungal infections. Wolf HH; Scharf RE; Arning M; Schneider W Haematol Blood Transfus; 1990; 33():560-2. PubMed ID: 2157647 [No Abstract] [Full Text] [Related]
7. Prophylaxis of fungal infections with itraconazole during remission-induction therapy. Prentice AG; Bradford GR Mycoses; 1989; 32 Suppl 1():96-102. PubMed ID: 2561190 [TBL] [Abstract][Full Text] [Related]
8. Safety and efficacy of itraconazole in prevention of fungal infections in neutropenic patients. Thunnissen PL; Sizoo W; Hendriks WD Neth J Med; 1991 Aug; 39(1-2):84-91. PubMed ID: 1660108 [TBL] [Abstract][Full Text] [Related]
9. Itraconazole treatment of pulmonary aspergillosis in leukaemia patients during a nosocomial epidemic associated with indoor building renovation. Brincker H; Christensen BE; Schmidt KG; Hornstrup MK Mycoses; 1991; 34(9-10):395-400. PubMed ID: 1668179 [TBL] [Abstract][Full Text] [Related]
10. Itraconazole for prophylaxis of systemic mycoses in neutropenic patients with haematological malignancies. Böhme A; Just-Nübling G; Bergmann L; Shah PM; Stille W; Hoelzer D J Antimicrob Chemother; 1996 Dec; 38(6):953-61. PubMed ID: 9023642 [TBL] [Abstract][Full Text] [Related]
11. [Itraconazole 800 mg for the prophylaxis of fungal infections in patients with acute leukemia and severe neutropenia]. Andrade M A; Puga L B; Guerra C C; Molina E J; Capurro C M Rev Med Chil; 2011 Sep; 139(9):1128-34. PubMed ID: 22215390 [TBL] [Abstract][Full Text] [Related]
13. Antifungal chemoprophylaxis in cancer children: a prospective randomized controlled study. Caselli D; Aricò M; Michelone G; Cavanna C; Nespoli L; Burgio GR Microbiologica; 1990 Oct; 13(4):347-51. PubMed ID: 1965007 [TBL] [Abstract][Full Text] [Related]
14. Evaluation of the practice of antifungal prophylaxis use in patients with newly diagnosed acute myeloid leukemia: results from the SEIFEM 2010-B registry. Pagano L; Caira M; Candoni A; Aversa F; Castagnola C; Caramatti C; Cattaneo C; Delia M; De Paolis MR; Di Blasi R; Di Caprio L; Fanci R; Garzia M; Martino B; Melillo L; Mitra ME; Nadali G; Nosari A; Picardi M; Potenza L; Salutari P; Trecarichi EM; Tumbarello M; Verga L; Vianelli N; Busca A; Clin Infect Dis; 2012 Dec; 55(11):1515-21. PubMed ID: 22955439 [TBL] [Abstract][Full Text] [Related]
15. Itraconazole. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in superficial and systemic mycoses. Grant SM; Clissold SP Drugs; 1989 Mar; 37(3):310-44. PubMed ID: 2540949 [TBL] [Abstract][Full Text] [Related]
16. Early experience with itraconazole in vitro and in patients: pharmacokinetic studies and clinical results. Dupont B; Drouhet E Rev Infect Dis; 1987; 9 Suppl 1():S71-6. PubMed ID: 3027850 [TBL] [Abstract][Full Text] [Related]
17. Fungal surveillance cultures during antifungal prophylaxis with itraconazole in neutropenic patients with acute leukaemia. Glasmacher A; Hahn C; Molitor E; Sauerbruch T; Schmidt-Wolf IG; Marklein G Mycoses; 1999; 42(5-6):395-402. PubMed ID: 10536431 [TBL] [Abstract][Full Text] [Related]
18. In vitro antifungal spectrum of itraconazole and treatment of systemic mycoses with old and new antimycotic agents. Van Cutsem J Chemotherapy; 1992; 38 Suppl 1():3-11. PubMed ID: 1319313 [TBL] [Abstract][Full Text] [Related]
19. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. Cornely OA; Maertens J; Winston DJ; Perfect J; Ullmann AJ; Walsh TJ; Helfgott D; Holowiecki J; Stockelberg D; Goh YT; Petrini M; Hardalo C; Suresh R; Angulo-Gonzalez D N Engl J Med; 2007 Jan; 356(4):348-59. PubMed ID: 17251531 [TBL] [Abstract][Full Text] [Related]
20. Prophylaxis of fungal infections with itraconazole in immunocompromised cancer patients. Mühldorfer SM; König HJ Mycoses; 1990 Jun; 33(6):291-5. PubMed ID: 2175392 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]